DuPont De Nemours (DD) Investor Day 2025 summary

Strategic transformation and portfolio focus

• Portfolio sharpened around healthcare, water technologies, and diversified industrials, with planned Electronics spin-off by November 1, 2025, and Aramids divestiture in early 2026, streamlining toward high-growth markets and secular trends.

• Healthcare and water now comprise 50% of revenue, targeted for further growth through M&A and organic investment, with bolt-on acquisitions prioritized in these segments.

• Transformation aims to reduce cyclicality, simplify operations, and decentralize decision-making for greater agility and accountability, supported by a performance-based culture.

• Recent divestitures, including Mobility & Materials and Aramids, have improved revenue growth and margin profile, generating $1.2 billion in cash proceeds from Aramids to be redeployed for value creation.

• Leadership team strengthened with new talent and a focus on building a high-performance, growth-oriented culture.

Growth strategy and business segment outlook

• Healthcare & Water Technologies expected to deliver mid-single-digit organic growth, leveraging innovation, OEM relationships, and trends like aging populations, biopharma, and water scarcity.

• Diversified Industrials (~$3.6B 2025E net sales, ~22% margin) targets margin expansion and steady growth through operational excellence, innovation in construction, EV, and automation.

• Building technologies focus on energy efficiency and sustainability, while industrial technologies leverage electrification and automation trends.

• Water business benefits from 70% recurring revenue, leadership in filtration and separation, and opportunities in lithium extraction and semiconductor ultra-pure water.

• Commercial excellence frameworks, lean operating models, and digital/AI tools are being implemented to drive growth, margin, and customer loyalty.

Financial guidance and capital allocation

• Medium-term targets (2025–2028): 3–4% organic sales CAGR, 150–200 bps EBITDA margin expansion (to 25–25.5%), 8–10% EPS CAGR, and >90% free cash flow conversion, with $8B top line and $2.7B–$2.8B free cash flow over three years.

• 2025 pro forma net sales expected at ~$6.9B, with operating EBITDA of ~$1.6B and a margin of 23.6%.

• Capital allocation prioritizes organic investment, 35–45% dividend payout, bolt-on M&A, and share repurchases, with $1.4–$1.5B excess cash available post-dividends for buybacks or acquisitions from 2026–2028.

• Maintains low leverage (<2x net debt/EBITDA), BBB+ credit rating, and a balanced approach to M&A and buybacks, with flexibility to respond to market dislocations.

• R&D spend to remain at ~2.5% of sales, CapEx to decline from 4% to 3% of sales by 2027, aided by contract manufacturing and disciplined capital deployment.